Editorials Subcutaneous apomorphine in Parkinson's disease BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7132.641 (Published 28 February 1998) Cite this as: BMJ 1998;316:641 Article Related content Metrics Responses Peer review Related articles Letter Extra cost of subcutaneous apomorphine would pay for personal nurses Published: 29 August 1998; BMJ 317 doi:10.1136/bmj.317.7158.602a See more Sixty seconds on . . . 10 000 steps BMJ March 08, 2024, 384 q598; DOI: https://doi.org/10.1136/bmj.q598 Scarlett McNally: Enabling active travel can improve the UK’s health BMJ March 06, 2024, 384 q522; DOI: https://doi.org/10.1136/bmj.q522 Scarlett McNally: Boosting swimming for health and joy BMJ February 20, 2024, 384 q393; DOI: https://doi.org/10.1136/bmj.q393 Variability in blood pressure could help predict heart attack and stroke risk, researchers say BMJ February 09, 2024, 384 q363; DOI: https://doi.org/10.1136/bmj.q363 Scarlett McNally: Preventing obesity is different from curing it—and even more urgent BMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134 Cited by... Practical considerations in the use of apomorphine injectableAbstract Fulltext Other formulations and future considerations for apomorphine for subcutaneous injection therapyAbstract Fulltext Restless legs syndromeAbstract Fulltext PDF Developments in the treatment of Parkinson's diseaseAbstract Fulltext PDF Extra cost of subcutaneous apomorphine would pay for personal nursesAbstract Fulltext PDF